KETAMINE IN THE TREATMENT OF PATIENTS WITH TREATMENT-RESISTANT UNIPOLAR DEPRESSION: RETROSPECTIVE STUDY

Abstract

Ketamine, originally an anesthetic discovered in 1962, has gained relevance in the treatment of psychiatric disorders, particularly treatment-resistant depression, due to its rapid antidepressant effects observed at sub-anesthetic doses. Previous studies indicate significant responses to intravenous administration, although long-term effects and other administration routes, such as the subcutaneous route, still require further investigation. The primary objective of this study is to assess the clinical evolution of patients with treatment-resistant unipolar depression treated with subcutaneous ketamine infusion. Secondary objectives include evaluating the progression of depressive symptoms in both short- and long-term phases, as well as identifying specific side effects associated with subcutaneous infusion. The study will involve patients treated between 2019 and 2024, diagnosed with treatment-resistant unipolar depression who have adopted subcutaneous ketamine infusion as a therapeutic method, excluding patients with diagnoses of substance abuse disorders, personality disorders, bipolar depression, and mixed disorder. Data collection will be conducted anonymously, based on a spreadsheet provided by the "Núcleo de Atenção ao Desenvolvimento Humano", with ethical assurances to protect participant privacy. It is expected that the results will contribute to a better understanding and clinical guidance on the use of subcutaneous ketamine in treatment-resistant depression, addressing knowledge gaps regarding its clinical application and long-term safety.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords